Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Affluent Medical S.A. is a medical technology company dedicated to the development of innovative healthcare solutions. With a focus on urology and interventional cardiology, the company is at the forefront of creating next-generation implants specifically designed to improve patients’ quality of life. Affluent Medical’s portfolio includes products such as artificial urinary sphincters and devices aimed at treating mitral valve insufficiency. By leveraging its expertise in minimally invasive techniques, the company addresses significant unmet medical needs, impacting healthcare sectors by providing advanced solutions for chronic conditions. Headquartered in France, Affluent Medical positions itself in the highly dynamic global medtech industry, contributing to significant advancements in patient care through its continuous research and development efforts.
€5.90
€0.14 (-2.32%)
EOD Aug 14, 2026
The business is unprofitable at the operating level (-355.44% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -€11M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€4M
Net Income (TTM)
-€15M
▲ +5.8% YoY
Op. Margin
-355.44%
ROIC
-24.35%
Cash Flow & Balance Sheet
FCF (TTM)
-€11M
▲ +6.3% YoY
Op. Cash Flow (TTM)
-€11M
▲ +6.2% YoY
Net Debt
€10M
Cash & Equiv.
€7M
Continue Research
Affluent Medical (AFME.XPAR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Affluent Medical scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Affluent Medical scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -355.4% operating margin and a -24.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AFME.XPAR's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.